| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 11029337 | European Journal of Cancer | 2018 | 11 Pages |
Abstract
After adjuvant FEC, ixabepilone was comparable to docetaxel for treating poor prognosis early BC patients. The benefit of ixabepilone in subgroups (patients with TNBC and grade II-III lymphocytic infiltration) requires further evaluation.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Mario Campone, Magali Lacroix-Triki, Lise Roca, Marc Spielmann, Hans Wildiers, Paul Cottu, Pierre Kerbrat, Christelle Levy, Isabelle Desmoulins, Thomas Bachelot, Tan Winston, Jean-Christophe Eymard, Lionel Uwer, Francois P. Duhoux, Didier Verhoeven,